<DOC>
	<DOC>NCT00822900</DOC>
	<brief_summary>The ProTECT study will determine if intravenous (IV) progesterone (started within 4 hours of injury and given for a total of 96 hours), is more effective than placebo for treating victims of moderate to severe acute traumatic brain injury.</brief_summary>
	<brief_title>Progesterone for the Treatment of Traumatic Brain Injury III</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Moderate to severe brain injury (GCS 124) Age 18 years or older Blunt, closed head injury Study drug initiated within 4 hours of injury NonSurvivable injury Bilateral dilated unresponsive pupils Severe intoxication (ETOH &gt; 250 mg %) Spinal cord injury with neurological deficits Inability to perform activities of daily living prior to injury Cardiopulmonary arrest Status epilepticus on arrival Systolic blood pressure (SBP) &lt; 90 on arrival or for at least 5 minutes prior to enrollment O2 Sat &lt; 90 on arrival or for at least 5 minutes prior to enrollment Prisoner or ward of state Pregnant Active breast or reproductive organ cancers Known allergy to progesterone or intralipid components (egg yolk) Known history of clotting disorder Active thromboembolic event Concern for inability to follow up at 6 months Anyone listed in the Opt out registry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Trauma</keyword>
	<keyword>Brain Injury</keyword>
</DOC>